Webinar Announcement: Accelerating Drug Discovery with GenAI

In today's rapidly evolving pharmaceutical landscape, the integration of artificial intelligence (AI) into drug discovery processes is revolutionising research and development. Traditional methods are often time-consuming and costly, but with the advent of Gen AI, biopharma companies can accelerate the identification of novel drug candidates, reduce expenses and enhance clinical success rates.

We are excited to invite you to an exclusive webinar titled "Accelerating Drug Discovery with Generative AI", where industry leaders from AWS and NVIDIA will delve into how AI-driven tools are transforming drug discovery - from target identification and protein design to virtual screening and lead optimisation.

Meet the presenters

Marissa E Powers, PhD, Solutions Architect, High Performance Computing (HPC) Life Sciences at Amazon Web Services (AWS)

Dr. Powers specialises in deploying R&D workloads on AWS, including molecular dynamics simulations, genomics pipelines, and Cryo-Electron microscopy. She holds a PhD in computational neuroscience and is dedicated to accelerating research and discovery.

David Ruau, PhD, EMEA Business Development Lead, Healthcare and Life Sciences at NVIDIA

Dr. Ruau brings extensive experience from his roles at Bayer Pharmaceuticals and AstraZeneca, where he led data science teams focusing on clinical trial optimisation and digital pathology. At NVIDIA, he concentrates on advancing AI applications in the healthcare sector across EMEA.

Neil Perry, Moderator, Group Broadcast Director at BizClik

Neil Perry brings two decades of multimedia experience to the discussion.

As Group Broadcast Director at BizClik, he has worked across major media platforms, providing expert commentary and facilitating discussions on business and industry trends. His background in news broadcasting and content leadership makes him the ideal moderator for this critical conversation.

Why Attend?

• Data-Driven Insights: Learn how generative AI models can manage massive, multi-modal datasets, predict molecular interactions, and swiftly generate novel drug candidates.

• Emerging Trends: Understand the latest advancements in AI-driven data integration, virtual screening, and de novo drug design.

• Proactive Strategies: Discover how AWS and NVIDIA's purpose-built solutions—from scalable cloud infrastructure to advanced AI microservices—facilitate the deployment and scaling of AI models in drug discovery.

Explore the latest edition of Cyber Magazine and be part of the conversation at our global conference series, Tech & AI LIVE and Cyber LIVE.

Discover all our upcoming events and secure your tickets today.

Cyber Magazine is a BizClik brand